Study name (Other identifier) | Sample size | Tx | Type of AML | Cytogenetic risk category | BMBC, median (range) | ||||
---|---|---|---|---|---|---|---|---|---|
De novo, n (%) | Secondary, n (%) | Therapy-related, n (%) | Poor, n (%) | Intermediate, n (%) | No mitosis, n (%) | ||||
AZA-AML-001 [20] | 241 | AZA | – | – | – | – | – | – | 66.6 (24.7%)a |
CALGB 11,002 [19] | 82 | DEC | – | – | – | – | – | – | – |
Short 2019 [21] | 28 | DEC 5-day | – | 13 (46.4) | – | – | – | – | 40 (29–68)b |
43 | DEC 10-day | – | 18 (41.9) | – | – | – | – | 46 (25–64)b | |
VIALE-A [6] | 145 | AZA | 110 (75.9) | 26 (17.9) | 9 (6.2) | 56 (38.6) | 89 (61.4) | – | – |
286 | VEN + AZA | 214 (74.8) | 46 (16.1) | 26 (9.1) | 104 (36.4) | 182 (63.6) | – | – | |
DiNardo 2018 [22] | 84 | VEN + AZA | – | – | – | 33 (39.3) | 50 (59.5) | 1 (1.2) | – |
31 | VEN + DEC | – | – | – | 15 (48.4) | 16 (51.6) | – | – | |
DiNardo 2020 [23] | 37 | VEN + DEC | – | – | – | – | – | – | 26 (–)a |
Kadia 2015 [24] | 293 | HDAC/HMA | – | – | – | – | – | – | – |
Short 2020 [25] | 202 | IDAC- or HDAC-based/HMA ± VEN | – | 30 (14.9) | 52 (25.7) | – | – | – | 32 (3–97) |
Lindsley 2019 [26] | 156 | 7 + 3 cytarabine + daunorubicin | – | – | – | – | – | – | – |
Prochazka 2019 [13] | 98 | IC | 82 (83.7) | 4 (4.1) | 12 (12.2) | 2 (2.0) | 11 (11.2) | 71 (72.4) | 60 (14–100) |
Chiche 2021 [27] | 103 | CPX-351 (daunorubicin + cytarabine) | – | – | 27 (26.2) | – | – | – | – |
Desoutter 2014 [28] | 96 | AZA | – | 53 (55.2) | 14 (14.6) | 61 (63.5) | 21 (21.9) | 14 (14.6) | 15 (0–95) |